Physician profile
Ana Phan
NPI 1972125706
$2,114.26
in general payments reported to CMS, 2019-2025
24 companies · $831 in 2025
The $831 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $56.24 · 2023: $454 · 2024: $773 · 2025: $831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,058.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,058.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $436.77 | 2023-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $282.82 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $247.95 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $210.84 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $131.68 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $110.62 | 2023-2025 | Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $94.87 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $76.78 | 2023-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.97 | 2022-2025 | Jardiance |
| Shield Therapeutics INC | $60.93 | 2023-2024 | Accrufer |
| Dynavax Technologies Corporation | $46.37 | 2024-2025 | Heplisav-B |
| Pfizer INC. | $44.50 | 2024 | |
| Esperion Therapeutics, INC. | $39.50 | 2024-2025 | Nexletol |
| Averitas Pharma INC. | $39.44 | 2025 | Qutenza |
| Astellas Pharma US INC | $38.29 | 2024-2025 | Veozah |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $35.23 | 2023-2025 | Dexcom G6 Transmitter |
| Baxter Healthcare | $33.26 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Sanofi-Aventis U.S. LLC | $26.67 | 2025 | |
| Abbott Laboratories | $22.83 | 2024 | Freestyle Libre 3 |
| Paratek Pharmaceuticals, INC. | $17.99 | 2025 | Nuzyra |
| Merck Sharp & Dohme LLC | $16.75 | 2025 | Gardasil 9, Capvaxive |
| Currax Pharmaceuticals LLC | $14.75 | 2025 | Contrave |
| Ibsa Pharma INC. | $14.01 | 2025 | Flector, Licart, Tirosint |
| Organon LLC | $6.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ana Phan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.